Bradley Canino
Stock Analyst at Stifel
(1.60)
# 3,491
Out of 5,241 analysts
83
Total ratings
33.78%
Success rate
-3.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Bradley Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintains: Buy | $9 → $8 | $2.28 | +250.88% | 2 | Mar 24, 2026 | |
| JANX Janux Therapeutics | Maintains: Buy | $46 → $38 | $13.89 | +173.58% | 4 | Dec 2, 2025 | |
| SNDX Syndax Pharmaceuticals | Reinstates: Buy | $44 | $20.23 | +117.50% | 7 | Sep 10, 2025 | |
| BDTX Black Diamond Therapeutics | Maintains: Buy | $16 → $15 | $2.75 | +445.45% | 5 | Mar 7, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Hold | $3 → $1.5 | $2.03 | -26.11% | 8 | Mar 7, 2025 | |
| CGEM Cullinan Therapeutics | Maintains: Buy | $23 → $19 | $15.73 | +20.79% | 2 | Feb 28, 2025 | |
| RLAY Relay Therapeutics | Maintains: Buy | $27 → $23 | $12.20 | +88.52% | 5 | Feb 27, 2025 | |
| ARVN Arvinas | Maintains: Buy | $63 → $51 | $9.08 | +461.67% | 6 | Feb 12, 2025 | |
| KURA Kura Oncology | Downgrades: Hold | $26 → $19 | $9.22 | +106.07% | 6 | Oct 14, 2024 | |
| CELC Celcuity | Maintains: Buy | $39 → $42 | $137.68 | -69.49% | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $40 | $16.87 | +137.11% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $135 | $102.30 | +31.96% | 4 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $8.15 | +145.40% | 1 | Sep 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $4.05 | +146.91% | 17 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $14 | $3.56 | +293.26% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $55 | $82.21 | -33.10% | 4 | Feb 23, 2024 |
Pyxis Oncology
Mar 24, 2026
Maintains: Buy
Price Target: $9 → $8
Current: $2.28
Upside: +250.88%
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $46 → $38
Current: $13.89
Upside: +173.58%
Syndax Pharmaceuticals
Sep 10, 2025
Reinstates: Buy
Price Target: $44
Current: $20.23
Upside: +117.50%
Black Diamond Therapeutics
Mar 7, 2025
Maintains: Buy
Price Target: $16 → $15
Current: $2.75
Upside: +445.45%
ALX Oncology Holdings
Mar 7, 2025
Maintains: Hold
Price Target: $3 → $1.5
Current: $2.03
Upside: -26.11%
Cullinan Therapeutics
Feb 28, 2025
Maintains: Buy
Price Target: $23 → $19
Current: $15.73
Upside: +20.79%
Relay Therapeutics
Feb 27, 2025
Maintains: Buy
Price Target: $27 → $23
Current: $12.20
Upside: +88.52%
Arvinas
Feb 12, 2025
Maintains: Buy
Price Target: $63 → $51
Current: $9.08
Upside: +461.67%
Kura Oncology
Oct 14, 2024
Downgrades: Hold
Price Target: $26 → $19
Current: $9.22
Upside: +106.07%
Celcuity
Oct 7, 2024
Maintains: Buy
Price Target: $39 → $42
Current: $137.68
Upside: -69.49%
Sep 25, 2024
Maintains: Buy
Price Target: $25 → $40
Current: $16.87
Upside: +137.11%
Sep 16, 2024
Maintains: Buy
Price Target: $115 → $135
Current: $102.30
Upside: +31.96%
Sep 6, 2024
Initiates: Buy
Price Target: $20
Current: $8.15
Upside: +145.40%
Jun 18, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $4.05
Upside: +146.91%
May 9, 2024
Maintains: Buy
Price Target: $13 → $14
Current: $3.56
Upside: +293.26%
Feb 23, 2024
Maintains: Buy
Price Target: $35 → $55
Current: $82.21
Upside: -33.10%